Back

The renin-angiotensin-aldosterone system assessment in patients with heart failure with mid-range ejection fraction of ischemic genesis in dependence of metabolic disorders

29 June 2021 (08:00 - 23:59)
Organised by:
Congress Presentation Part of: ePoster session Heart Failure with Mid-Range Ejection Fraction (HFmrEF) HFA Premium Access Heart Failure 2021

About the speaker

Photo
Associate Professor Olga Godlevska

Kharkiv Medical Academy of Postgraduate Education, Kharkiv (Ukraine)

738 More presentations in this session

Presentation thumbnail
Atrial lead insertion during cardiac implantable electronic devices implantation in patients with atrial arrhythmia on hospital admission, when does the struggle for sinus rhythm make sense?
Assistant Professor N. Radovanovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Features of the remodeling of atria and pulmonary veins in CHF patients with paroxysmal AF and permanent AF
Assistant Professor V. Kirillova (Ekaterinburg, RU)
Abstract Slides
Presentation thumbnail
Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum
Doctor D. Moysidis (Zurich, CH)
Abstract Slides
Presentation thumbnail
Impact of cardiac contractility modulation on ventricular rhythm and conduction disorders in patients with heart failure with reduced ejection fraction and various forms of atrial fibrillation
Doctor A. Safiullina (Moscow, RU)
Abstract Slides
Presentation thumbnail
Was a difference between late and early new-onset of atrial fibrillation in non st-elevation myocardial infarction?
Doctor H. Santos (Lisboa, PT)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

Heart Failure 2021

29 June 2021 08:00 CET
You may be interested in
thumbnail
Congress Session
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?
thumbnail
Congress Presentation
Cardio-Kidney-Metabolic Overlap in the FINEARTS-HF Trial
thumbnail
Congress Presentation
Plasma aldosterone concentration / plasma renin activity ratio in patients with essential hypertension before treatment

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources